Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.72 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.72 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.68 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.67 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.67 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.67 |
| ▸ | LDHA | P00338 | 1/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.67 |
| ▸ | FBP1 | P09467 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.67 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.67 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.67 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9702967 | 1.00 | SIRT2 (0.72) | SIRT2SIRT1ENTPD1TRPM2DNPH1 | |
| SCHEMBL20277574 | 1.00 | SIRT2 (0.72) | SIRT2SIRT1ENTPD1TRPM2DNPH1 | |
| SCHEMBL20277592 | 1.00 | SIRT2 (0.72) | SIRT2SIRT1ENTPD1TRPM2DNPH1 | |
| SCHEMBL19668316 | 0.93 | SIRT2 (0.63) | SIRT2SIRT1ENTPD1TRPM2DNPH1 | |
| SCHEMBL9752397 | 0.92 | ENTPD1 (0.74) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL9752399 | 0.92 | ENTPD1 (0.74) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL30292631 | 0.92 | ENTPD1 (0.76) | ENTPD1TRPM2SRCP2RY2P2RY1 | |
| SCHEMBL12932272 | 0.92 | ENTPD1 (0.76) | ENTPD1TRPM2SRCP2RY2P2RY1 | |
| SCHEMBL1062562 | 0.92 | ENTPD1 (0.76) | ENTPD1TRPM2SRCP2RY2P2RY1 | |
| SCHEMBL31685855 | 0.90 | SIRT2 (0.75) | SIRT2SIRT1ENTPD1TRPM2DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2025-05-22 | — | — | US | disclosed |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2024-08-06 | — | — | US | disclosed |
| EP-4403042-A2 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2022-09-29 | — | — | US | disclosed |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20180168208-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2017207989-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | NUCANA BIOMED LIMITED (GB) | 2017-12-07 | — | — | WO | disclosed |
| EP-3224268-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana BioMed Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2017-09-07 | — | — | US | disclosed |
| WO-2016083830-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| EP-0499291-A1 | Treatment of malignant tumours with 8-chloroadenosine 3'-5'-cyclic phosphate, 8-aminoadenosine 3',5'-cyclic phosphate and preparation thereof | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1992-08-19 | — | — | EP | disclosed |
| EP-0346400-A4 | TREATMENT OF MALIGNANT TUMORS WITH 8-CHLOROADENOSINE 3',5'-CYCLIC PHOSPHATE, 8-AMINOADENOSINE 3',5'-CYCLIC PHOSPHATE AND PREPARATION THEREOF | — | 1990-11-28 | — | — | EP | disclosed |
| EP-0346400-A1 | TREATMENT OF MALIGNANT TUMORS WITH 8-CHLOROADENOSINE 3',5'-CYCLIC PHOSPHATE, 8-AMINOADENOSINE 3',5'-CYCLIC PHOSPHATE AND PREPARATION THEREOF | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1989-12-20 | — | — | EP | disclosed |
| US-4861873-A | 8-Chloroadenosine 3', 5'-cyclic monophosphate preparations | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1989-08-29 | — | — | US | disclosed |
| WO-1989005648-A1 | TREATMENT OF MALIGNANT TUMORS WITH 8-CHLOROADENOSINE 3',5'-CYCLIC PHOSPHATE, 8-AMINOADENOSINE 3',5'-CYCLIC PHOSPHATE AND PREPARATION THEREOF | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | SIRT2 3278/4885SIRT1 2887/4885ENTPD1 62/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | SIRT2 3555/4885SIRT1 3516/4885ENTPD1 3590/4885 |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, ADA, ADORA2A | SIRT2 3254/4885SIRT1 2842/4885ENTPD1 60/4885 |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, RNMT, ADA | SIRT2 3628/4885SIRT1 3067/4885ENTPD1 88/4885 |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | SIRT2 3278/4885SIRT1 2887/4885ENTPD1 62/4885 |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | SIRT2 3593/4885SIRT1 3051/4885ENTPD1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.